quest13, thanks for the insight.

I've been in RVX for 8 years, hence ended up with Zenith shares. I'm really surprised about what I consider to be a low valuation for Zenith at $1.00US but I guess at this early stage nothing is proven (other than in vitro and in vivo) in terms of any of the compounds including zen3694.

On the other hand apabetalone (rvx-208) has strong clinical evidence of MACE reduction in trials and a proven safety profile out to 6 months.

I have not heard any evidence at this stage that KD/Eastern has treated retail shareholders unfairly at RVX or any company to date as far as I know. With RVX there are the counter-balancing influences of NGN, Hepalink, CD Venture and the shares held by Don and Dr Wong along with Don's relatives, etc. So I am guessing that Eastern's intentions are good and you are probably right about the brokers indicating Zenith at this stage would only get 10 cents.

If the results of the prostate trial of zen3694 are significant and positive then the findings will begin to trickle out early (the trial is not double blind and allows for ongoing monitoring) and this could have a very positive impact.

My bet is that there is so much upside to this science and hence RVX and Zenith that once one of the trials proves their hypothesis it will legitimize the entire BET inhibition science and drive investment interest through the roof!

I guess we'll see. I'm long!

Toinv